Clearmind Medicine, a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, Israel.
The treatment used in the trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, obesity and metabolic disorders and depression, and SciSparc's Palmitoylethanolamide (PEA), which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide.
The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioural parameters including fat oxidation, locomotor activity, and feeding behaviour.
Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that:
The administered treatment exhibited a remarkable degree of tolerance, leaving the mice' viability unaffected across all experimental groups.
Combining MEAI and PEA, particularly at 20 and 10mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. Oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn.
A striking reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20mg/kg of MEAI.
Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10mg/kg.
At 40 and 20mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.
"We are excited by these latest results of our combination treatment for obesity and metabolic disorders. Over the past year, we have witnessed an increased demand of medication for weight loss, even though they exhibit severe side effects and have even lead to hospitalization. I believe that our proprietary drug candidate, MEAI, is a potentially better and safer option compared to other weight-loss drugs currently on the market due to previous and current positive results and the very good safety profile," said Dr Adi Zuloff-Shani, Clearmind's Chief Executive Officer. "Clearmind's treatment targets fat loss while maintaining and elevating energy levels, motivation and other positive influences. These latest results strengthen our confidence in our MEAI-based treatment, including our combination treatment with SciSparc's PEA."
"These results from the pre-clinical trial highlight the promising potential of Clearmind's MEAI and SciSparc's PEA combination treatment for obesity and metabolic disorders. The observed increase in metabolic processes, fat oxidation, and reduced appetite signify a significant step forward in developing safer and effective therapies for weight management," said Professor Joseph Tam of The Hebrew University of Jerusalem.